menu
    • menu
    [{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Inflamax Research | Metronomia Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Inflamax Research | Metronomia Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Inflamax Research | Metronomia Clinical Research"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Syneos Health | Metronomia Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Syneos Health | Metronomia Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ Syneos Health | Metronomia Clinical Research"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Grass MATA MPL Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Ecarf Institute GmbH | Bencard Allergie GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"holoBLG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PQGrass306","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PQGrass309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tree MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ AGC Biologics"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP-based Peanut Allergy Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Allergy Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Therapeutics \/ Allergy Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Allergy Therapeutics

    Menu

    Allergy Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PQGrass306

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced...

                            Details : PQGrass306 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 15, 2022

                            Lead Product(s) : PQGrass306

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

                            Details : VLP Peanut is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 27, 2022

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : holoBLG

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Ecarf Institute GmbH | Bencard Allergie GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of holoBLG on Cat Allergic Patients

                            Details : HoloBLG is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 13, 2022

                            Lead Product(s) : holoBLG

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Ecarf Institute GmbH | Bencard Allergie GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate

                            Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP-based Peanut Allergy Vaccine

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Recipient : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

                            Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : VLP-based Peanut Allergy Vaccine

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Recipient : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PQGrass309

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Exploratory Study of PQ Grass 27600 SU

                            Details : PQGrass309 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 29, 2020

                            Lead Product(s) : PQGrass309

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Grass MATA MPL

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Announces Start of Innovative Exploratory Field Study to Evaluate Efficacy and Safety of ...

                            Details : Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.

                            Product Name : Grass MATA MPL

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : Grass MATA MPL

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tree MATA MPL

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Announces Invalidation of the Birch MATA MPL Phase III Primary Endpoint Results

                            Details : Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergen...

                            Product Name : Tree MATA MPL

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 09, 2020

                            Lead Product(s) : Tree MATA MPL

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Grass MATA MPL

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Syneos Health | Metronomia Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

                            Details : Grass MATA MPL is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 30, 2019

                            Lead Product(s) : Grass MATA MPL

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Syneos Health | Metronomia Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Grass MATA MPL Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECsââ...

                            Details : Grass MATA MPL Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            October 21, 2015

                            Lead Product(s) : Grass MATA MPL Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth